Meeting
2020 Genitourinary Cancers Symposium
Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).
Authors
Andrew James Weickhardt
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Melbourne, Australia
Andrew James Weickhardt , Farshad Foroudi , Nathan Lawrentschuk , Laura Galleta , Amanda Seegum , Alan Herschtal , Emma Link , Margaret Mary McJannett , Elizabeth Chien Hern Liow , Peter S. Grimison , Alison Yan Zhang , NItya Patanjali , Siobhan Ng , Robert Goodwin , Colin Tang , Colin Chen , Elizabeth J. Hovey , George Hruby , Alexander David Guminski , Ian D. Davis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02662062
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 485)
Abstract #
485
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
First Author: Andrew James Weickhardt
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck